Slow Response to Clopidogrel Predicts Low Response

Journal of the American College of Cardiology

Volumn 55, Issue 8, 2010, Pages 815-822

  Bellemain Appaix, Anne ^a   Montalescot, Gilles ^a   Silvain, Johanne ^a   Barthélémy, Olivier ^a   Beygui, Farzin ^a   Collet, Jean Philippe ^a   Sideris, Georges ^b   Meuleman, Catherine ^c   Bal dit Sollier, Claire ^b   Lellouche, Nicolas ^d   Ducrocq, Grégory ^e   Slama, Michel ^d   Milleron, Olivier ^f   Henry, Patrick ^b   Drouet, Ludovic ^b  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^b HÔPITAL LARIBOISIÈRE   (France)

^c HÔPITAL SAINT ANTOINE   (France)

^d ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

^e BICHAT HOSPITAL   (France)

^f HÔPITAL AMBROISE PARÉ   (France)

Author keywords

acute coronary syndromes; clopidogrel; platelets

Indexed keywords

ACETYLSALICYLIC ACID; ADENOSINE DIPHOSPHATE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CLOPIDOGREL; CREATININE; DUAL SPECIFICITY PHOSPHATASE 2; HEMOGLOBIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; NITRATE; PADGEM PROTEIN; TROPONIN; VASODILATOR STIMULATED PHOSPHOPROTEIN;

ACUTE CORONARY SYNDROME; ADULT; ARTICLE; BODY MASS; CARDIAC PATIENT; CARDIOVASCULAR RISK; CASE REPORT; CIGARETTE SMOKING; CREATININE BLOOD LEVEL; DIABETES MELLITUS; DOSE RESPONSE; DRUG DOSE COMPARISON; ELECTROCARDIOGRAPHY; FEMALE; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; LOADING DRUG DOSE; LONG TERM CARE; MALE; NEUTROPHIL COUNT; POST HOC ANALYSIS; PREDICTION; PRIORITY JOURNAL; ST SEGMENT DEPRESSION; THROMBOCYTE AGGREGATION; THROMBOCYTE COUNT; TREATMENT RESPONSE;

ACUTE CORONARY SYNDROME; ADENOSINE DIPHOSPHATE; AGED; BIOMARKERS, PHARMACOLOGICAL; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; MALE; MIDDLE AGED; PLATELET AGGREGATION; PLATELET AGGREGATION INHIBITORS; TICLOPIDINE; TREATMENT OUTCOME;

EID: 76449094672     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jacc.2009.08.082     Document Type: Article

References (33)

1. Sabatine M.S., Cannon C.P., Gibson C.M., et al. Effect of clopidogrel pretreatment before percutaneous coronary intervention in patients with ST-elevation myocardial infarction treated with fibrinolytics: the PCI-CLARITY study. JAMA 294 (2005) 1224-1232
2. Mehta S.R., Yusuf S., Peters R.J., et al. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study. Lancet 358 (2001) 527-533
3. Matetzky S., Shenkman B., Guetta V., et al. Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction. Circulation 109 (2004) 3171-3175
4. Cuisset T., Frere C., Quilici J., et al. Benefit of a 600-mg loading dose of clopidogrel on platelet reactivity and clinical outcomes in patients with non-ST-segment elevation acute coronary syndrome undergoing coronary stenting. J Am Coll Cardiol 48 (2006) 1339-1345
5. Gurbel P.A., Samara W.M., and Bliden K.P. Failure of clopidogrel to reduce platelet reactivity and activation following standard dosing in elective stenting: implications for thrombotic events and restenosis. Platelets 15 (2004) 9-59
6. Bonello L., Camoin-Jau L., Arques S., et al. Adjusted clopidogrel loading doses according to vasodilator-stimulated phosphoprotein phosphorylation index decrease rate of major adverse cardiovascular events in patients with clopidogrel resistance: a multicenter randomized prospective study. J Am Coll Cardiol 51 (2008) 1404-1411
7. Montalescot G., Sideris G., Meuleman C., et al. A randomized comparison of high clopidogrel loading doses in patients with non-ST-segment elevation acute coronary syndromes: the ALBION (Assessment of the Best Loading Dose of Clopidogrel to Blunt Platelet Activation, Inflammation and Ongoing Necrosis) trial. J Am Coll Cardiol 48 (2006) 931-938
8. Patti G., Colonna G., Pasceri V., Pepe L.L., Montinaro A., and Di Sciascio G. Randomized trial of high loading dose of clopidogrel for reduction of periprocedural myocardial infarction in patients undergoing coronary intervention: results from the ARMYDA-2 (Antiplatelet therapy for Reduction of MYocardial Damage during Angioplasty) study. Circulation 111 (2005) 2099-2106
9. Muller I., Seyfarth M., Rudiger S., et al. Effect of a high loading dose of clopidogrel on platelet function in patients undergoing coronary stent placement. Heart 85 (2001) 92-93
10. Hochholzer W., Trenk D., Frundi D., et al. Time dependence of platelet inhibition after a 600-mg loading dose of clopidogrel in a large, unselected cohort of candidates for percutaneous coronary intervention. Circulation 111 (2005) 2560-2564
11. Gurbel P.A., Bliden K.P., Zaman K.A., Yoho J.A., Hayes K.M., and Tantry U.S. Clopidogrel loading with eptifibatide to arrest the reactivity of platelets: results of the Clopidogrel Loading With Eptifibatide to Arrest the Reactivity of Platelets (CLEAR PLATELETS) study. Circulation 111 (2005) 1153-1159
12. Thebault J.J., Kieffer G., and Cariou R. Single-dose pharmacodynamics of clopidogrel. Semin Thromb Hemost 25 Suppl 2 (1999) 3-8
13. Angiolillo D.J., Fernandez-Ortiz A., Bernardo E., et al. High clopidogrel loading dose during coronary stenting: effects on drug response and interindividual variability. Eur Heart J 25 (2004) 1903-1910
14. Collet J.P., Silvain J., Landivier A., et al. Dose effect of clopidogrel reloading in patients already on 75-mg maintenance dose: the Reload with Clopidogrel Before Coronary Angioplasty in Subjects Treated Long Term with Dual Antiplatelet Therapy (RELOAD) study. Circulation 118 (2008) 1225-1233
15. Ang L., Palakodeti V., Khalid A., et al. Elevated plasma fibrinogen and diabetes mellitus are associated with lower inhibition of platelet reactivity with clopidogrel. J Am Coll Cardiol 52 (2008) 1052-1059
16. Cuisset T., Frere C., Quilici J., et al. Relationship between aspirin and clopidogrel responses in acute coronary syndrome and clinical predictors of non response. Thromb Res 123 (2009) 597-603
17. Motovska Z., Widimsky P., Petr R., et al. Factors influencing clopidogrel efficacy in patients with stable coronary artery disease undergoing elective percutaneous coronary intervention: statin's advantage and the smoking "paradox.". J Cardiovasc Pharmacol 53 (2009) 368-372
18. Lau W.C., Waskell L.A., Watkins P.B., et al. Atorvastatin reduces the ability of clopidogrel to inhibit platelet aggregation: a new drug-drug interaction. Circulation 107 (2003) 32-37
19. Siller-Matula J.M., Lang I., Christ G., and Jilma B. Calcium-channel blockers reduce the antiplatelet effect of clopidogrel. J Am Coll Cardiol 52 (2008) 1557-1563
20. Sibbing D., Morath T., Stegherr J., et al. Impact of proton pump inhibitors on the antiplatelet effects of clopidogrel. Thromb Haemost 101 (2009) 714-719
21. Gurbel P.A., Bliden K.P., Hiatt B.L., and O'Connor C.M. Clopidogrel for coronary stenting: response variability, drug resistance, and the effect of pretreatment platelet reactivity. Circulation 107 (2003) 2908-2913
22. Collet J.P., Hulot J.S., Pena A., et al. Cytochrome P450 2C19 polymorphism in young patients treated with clopidogrel after myocardial infarction: a cohort study. Lancet 373 (2009) 309-317
23. Bliden K.P., Dichiara J., Lawal L., et al. The association of cigarette smoking with enhanced platelet inhibition by clopidogrel. J Am Coll Cardiol 52 (2008) 531-533
24. Weerakkody G.J., Jakubowski J.A., Brandt J.T., et al. Comparison of speed of onset of platelet inhibition after loading doses of clopidogrel versus prasugrel in healthy volunteers and correlation with responder status. Am J Cardiol 100 (2007) 331-336
25. Tschoepe D., Schultheiss H.P., Kolarov P., et al. Platelet membrane activation markers are predictive for increased risk of acute ischemic events after PTCA. Circulation 88 (1993) 37-42
26. Barragan P., Bouvier J.L., Roquebert P.O., et al. Resistance to thienopyridines: clinical detection of coronary stent thrombosis by monitoring of vasodilator-stimulated phosphoprotein phosphorylation. Catheter Cardiovasc Interv 59 (2003) 295-302
27. Cuisset T., Frere C., Quilici J., et al. Lack of association between the 807 C/T polymorphism of glycoprotein Ia gene and post-treatment platelet reactivity after aspirin and clopidogrel in patients with acute coronary syndrome. Thromb Haemost 97 (2007) 212-217
28. Gurbel P.A., Bliden K.P., Samara W., et al. Clopidogrel effect on platelet reactivity in patients with stent thrombosis: results of the CREST study. J Am Coll Cardiol 46 (2005) 1827-1832
29. Morel O., Viellard C., Faure A., et al. Platelet responsiveness to clopidogrel in patients with coronary syndrome. Comparison of platelet aggregation induced by ADP and flow cytometric analysis of intraplatelet VASP phosphorylation. Ann Cardiol Angiol (Paris) 56 (2007) 21-29
30. Malinin A., Pokov A., Spergling M., et al. Monitoring platelet inhibition after clopidogrel with the VerifyNow-P2Y12(R) rapid analyzer: the VERIfy Thrombosis risk ASsessment (VERITAS) study. Thromb Res 119 (2007) 277-284
31. Pena A., Collet J.P., Hulot J.S., et al. Can we override clopidogrel resistance?. Circulation 119 (2009) 2854-2857
32. Valgimigli M., Campo G., de Cesare N., et al. Intensifying platelet inhibition with tirofiban in poor responders to aspirin, clopidogrel, or both agents undergoing elective coronary intervention: results from the double-blind, prospective, randomized Tailoring Treatment with Tirofiban in Patients Showing Resistance to Aspirin and/or Resistance to Clopidogrel study. Circulation 119 (2009) 3215-3222
33. Michelson A.D., Frelinger III A.L., Braunwald E., et al. Pharmacodynamic assessment of platelet inhibition by prasugrel vs. clopidogrel in the TRITON-TIMI 38 trial. Eur Heart J 30 (2009) 1753-1763